"In value-based pricing, drugs that are associated with greater improvements to the same end point or more improved objective end points (ie, PFS rather than ORR, OS rather than PFS) would be expected to cost more. The results of this analysis suggest the opposite: oncology drugs approved based on OS improvement had the lowest median annual cost of the 3 end points."

https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2798197